Qiagen stock last at EUR 38.72 on September 30, 2026
Published on 10/01/2026 at 08:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen N.V. stock was last at EUR 38.72 on September 30, 2026, at 5:37 p.m. CEST, according to market data for the German listing.
FDA clearance expands QIAstat-Dx portfolio
On September 28, 2026, QIAGEN said U.S. laboratories had access to its complete QIAstat-Dx bloodstream infection portfolio after the U.S. Food and Drug Administration cleared a new panel.
The QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers in about one hour. Together with the previously cleared gram-positive bacteria and fungi panel, the two tests cover 33 pathogen targets and 28 antibiotic resistance markers, according to the company.
Product footprint
QIAGEN said the QIAstat-Dx system was available in more than 100 countries and had more than 5,200 cumulative placements at the end of 2025.
